跳转到主要内容

Chemotherapy after surgery versus surgery alone for stomach cancer

Stomach cancer is the second leading cause of cancer-related death worldwide. Surgery is the only curative treatment offered to patients suffering from this cancer. Survival rates, however, are still poor. Chemotherapy given after surgery has been developed in order to improve these results. We identified 34 trials with 7824 patients which randomised patients to surgery with post-surgical chemotherapy versus surgery alone. The group who received chemotherapy had a survival benefit and improvement in disease free survival (15% and 21%, respectively), although all the trials had a high risk of bias. There was no significant difference due to the stage of disease or the chemotherapy agent used.

研究背景

For gastric cancer surgery is the mainstay treatment. Chemotherapy seems to improve the survival results. But chemotherapy is not a complication-free therapy and its role has been questioned by some trials.

研究目的

To determine whether post-surgical chemotherapy should be used routinely in resectable gastric cancer.

检索策略

We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded (July 2013).

纳入排除标准

Randomised controlled trials (RCT) comparing post-surgical chemotherapy versus surgery alone for resectable gastric cancer.

资料收集与分析

Two authors independently assessed trials for inclusion and independently extracted the data. We analysed the data with both the fixed-effect and the random-effects models using the RevMan analysis software. We calculated the hazard ratio (HR) with 95% confidence interval (CI) based on intention-to-treat or available case analysis.

主要结果

The authors identified 34 studies (7824 patients) reporting overall survival (OS) and only 15 reporting disease free survival (DFS) as well. Post-surgical chemotherapy showed an improvement in OS (HR 0.85; 95% CI 0.80 to 0.90) and an improvement in DFS (HR 0.79; 95% CI 0.72 to 0.87), although all the trials had a high risk of bias.

The planned analysis of quality of life, return to work, and number of hospital admissions was impossible to complete as the outcome data for the analysis were not available from any trials.

作者结论

Post-surgical chemotherapy should be used routinely for resectable gastric cancer where possible. Further RCTs are needed to determine the role at each stage of disease.

引用文献
Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD008415. DOI: 10.1002/14651858.CD008415.pub2.

我们的Cookie使用

我们使用必要的cookie来使我们的网站工作。我们还希望设置可选的分析cookie,以帮助我们进行改进。除非您启用它们,否则我们不会设置可选的cookie。使用此工具将在您的设备上设置一个cookie来记住您的偏好。您随时可以随时通过单击每个页面页脚中的“Cookies设置”链接来更改您的Cookie首选项。
有关我们使用cookie的更多详细信息,请参阅我们的Cookies页面

接受全部
配置